What are the guideline sources, guidelines and references for Hereditary breast and ovarian cancer ?
Guideline sources The following summarized guidelines for the evaluation and management of hereditary breast and ovarian cancer (HBOC) are prepared by our editorial team based on guidelines from the U.S. Preventive Services Task Force (USPSTF 2014) and the National Society of Genetic Counselors (NSGC 2013). 1 2 Calculator Calculator Calculator Eastern Cooperative Oncology G FIGO staging for ovarian cancer Karnofsky Guidelines 1. Screening and diagnosis Indications for screening: As per USPSTF 2014 guidelines: Screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes such as BRCA1 or BRCA2. B https://web.pathway.md/diseases/recLD1PXcWPEPbK9p 1/3 6/24/23, 12:41 PM Hereditary breast and ovarian cancer Pathway Avoid routine BRCA testing for women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes. D As per USPSTF 2014 guidelines: Screen for mutations in breast cancer susceptibility genes (including BRCA1 or BRCA2) in women who have family members with breast, ovarian, tubal, or peritoneal cancer. Use a screening tool designed to identify a family history that may be associated with an increased risk. B Provide genetic counseling and, if indicated after counseling, BRCA testing in women with positive screening results. B 2. Diagnostic investigations Genetic testing: consult published guidelines regarding the appropriateness of genetic testing, and address a more tailored approach to medical management. Risk assessment: follow the standards of care for accurate risk assessment when identifying individuals at risk for breast and/or ovarian cancers. Consider established models and published data to estimate the individual's risk of developing cancer, as this will assist in determining appropriate management. E 3. Patient education Genetic counseling: As per USPSTF 2014 guidelines: Provide genetic counseling and, if indicated after counseling, BRCA testing for women with positive screening results. B Avoid routine genetic counseling for women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes. D As per NSGC 2013 guidelines, provide access to resources including scientific information, psychosocial support, and advocacy as part of the genetics consultation for patients with suspected HBOC. E References 1. Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Feb 18;160 4 271 81. Open 2. Berliner JL, Fay AM, Cummings SA et al. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013 Apr;22 2 155 63. Open 3. Anne Grabenstetter, Conxi Lazaro, Gulisa Turashvili. Editorial: Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment. Front Oncol. 2020 Dec 2;10 618369. Open https://web.pathway.md/diseases/recLD1PXcWPEPbK9p 2/3 6/24/23, 12:41 PM Hereditary breast and ovarian cancer Pathway 4. Samantha Greenberg, Saundra S Buys, Sandra L Edwards et al. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing. Cancer Med. 2019 Nov;8 15 6789 6798. Open 5. Anna fverholm, Zakaria Einbeigi, Antonia Wigermo et al. Increased Overall Mortality Even after Risk Reducing Surgery for BRCA Positive Women in Western Sweden. Genes Basel). 2019 Dec 16;10 12 1046. Open 6. Megan Marshall, Sheila Solomon. Hereditary breast-ovarian cancer: clinical findings and medical management. Plast Surg Nurs. Jul-Sep 2007;27 3 124 7. Open 7. Michelle Jacobson, Marcus Bernardini, Mara L Sobel et al. No. 366 Gynaecologic Management of Hereditary Breast and Ovarian Cancer. J Obstet Gynaecol Can. 2018 Nov;40 11 1497 1510. Open 8. S Paluch-Shimon, F Cardoso, C Sessa et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016 Sep;27(suppl 5):v103-v110. Open https://web.pathway.md/diseases/recLD1PXcWPEPbK9p 3/3